In a recent 12-month study investigating the cardiometabolic effects of dulaglutide in 65 Caucasian patients with T2DM, Al Refaie et al. reported that treatment with GLP-1 RAs, including dulaglutide, led not only to a significant reduction in LDL-cholesterol and triglyceride levels but also to a significant increase in serum adiponectin levels, indicating reduced insulin resistance and inflammatory activity. Here, ADIPOQ is linked to type 2 diabetes mellitus.